The European Academy of Neurology NeuroCOVID-19 Task Force: A lesson for the future.
COVID‐19
EAN
SARS‐Cov‐2
neurology
pandemic
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
received:
19
03
2024
accepted:
11
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
27
4
2024
Statut:
aheadofprint
Résumé
The COVID-19 pandemic has made its mark on world history forever causing millions of deaths, and straining health systems, economies, and societies worldwide. The European Academy of Neurology (EAN) reacted promptly. A special NeuroCOVID-19 Task Force was set up at the beginning of the pandemic to promote knowledge, research, international collaborations, and raise awareness about the prevention and treatment of COVID-19-related neurological issues. Activities carried out during and after the pandemic by the EAN NeuroCOVID-19 Task Force are described. The main aim was to review all these initiatives in detail as an overarching lesson from the past to improve the present and be better prepared in case of future pandemics. During the pandemic, the Task Force was engaged in several initiatives: the creation of the EAN NEuro-covid ReGistrY (ENERGY); the launch of several surveys (neurological manifestations of COVID-19 infection; the pandemic's impact on patients with chronic neurological diseases; the pandemic's impact of restrictions for clinical practice, curricular training, and health economics); the publication of position papers regarding the management of patients with neurological diseases during the pandemic, and vaccination hesitancy among people with chronic neurological disorders; and the creation of a dedicated "COVID-19 Breaking News" section in EANpages. The EAN NeuroCOVID-19 Task Force was immediately engaged in various activities to participate in the fight against COVID-19. The Task Force's concerted strategy may serve as a foundation for upcoming global neurological emergencies.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has made its mark on world history forever causing millions of deaths, and straining health systems, economies, and societies worldwide. The European Academy of Neurology (EAN) reacted promptly. A special NeuroCOVID-19 Task Force was set up at the beginning of the pandemic to promote knowledge, research, international collaborations, and raise awareness about the prevention and treatment of COVID-19-related neurological issues.
METHODS
METHODS
Activities carried out during and after the pandemic by the EAN NeuroCOVID-19 Task Force are described. The main aim was to review all these initiatives in detail as an overarching lesson from the past to improve the present and be better prepared in case of future pandemics.
RESULTS
RESULTS
During the pandemic, the Task Force was engaged in several initiatives: the creation of the EAN NEuro-covid ReGistrY (ENERGY); the launch of several surveys (neurological manifestations of COVID-19 infection; the pandemic's impact on patients with chronic neurological diseases; the pandemic's impact of restrictions for clinical practice, curricular training, and health economics); the publication of position papers regarding the management of patients with neurological diseases during the pandemic, and vaccination hesitancy among people with chronic neurological disorders; and the creation of a dedicated "COVID-19 Breaking News" section in EANpages.
CONCLUSIONS
CONCLUSIONS
The EAN NeuroCOVID-19 Task Force was immediately engaged in various activities to participate in the fight against COVID-19. The Task Force's concerted strategy may serve as a foundation for upcoming global neurological emergencies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16321Investigateurs
Michael Crean
(M)
Giovanni Di Liberto
(G)
Thomas Jenkins
(T)
Maria Konti
(M)
Maurizio Leone
(M)
Antonella Macerollo
(A)
Luis Maia
(L)
Celia Oreja-Guevara
(C)
Antonio Pisani
(A)
Michele Romoli
(M)
Anna Sauerbier
(A)
Riccardo Soffietti
(R)
Pille Taba
(P)
Marialuisa Zedde
(M)
Benedetta Bodini
(B)
Ettore Beghi
(E)
Informations de copyright
© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Moro E, Taba P. COVID‐19: an unforgettable challenge for the neurology community. Eur J Neurol. 2021;28(10):3221‐3222. doi:10.1111/ene.14937
World Health Organizaion (WHO). Coronavirus disease (COVID‐19) pandemic. https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019
Moro E, Fernandez HH. Adaptive neurology in COVID‐19 times. Parkinsonism Relat Disord. 2020;75:124‐125. doi:10.1016/j.parkreldis.2020.06.003
Fanciulli A, Leys F, Krbot Skorić M, et al. Impact of the COVID‐19 pandemic on clinical autonomic practice in Europe: a survey of the European Academy of Neurology and the European Federation of Autonomic Societies. Eur J Neurol. 2023;30(6):1712‐1726. doi:10.1111/ene.15787
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733. doi:10.1056/NEJMoa2001017
Cavallieri F, Sellner J, Zedde M, Moro E. Neurologic complications of coronavirus and other respiratory viral infections. Handbook of Clinical Neurology. Vol 189. Elsevier; 2022:331‐358. doi:10.1016/B978-0-323-91532-8.00004-5
Reis Carneiro D, Rocha I, Habek M, et al. Clinical presentation and management strategies of cardiovascular autonomic dysfunction following a COVID ‐19 infection – a systematic review. Eur J Neurol. 2023;30(5):1528‐1539. doi:10.1111/ene.15714
Fedorowski A, Fanciulli A, Raj SR, Sheldon R, Shibao CA, Sutton R. Cardiovascular autonomic dysfunction in post‐COVID‐19 syndrome: a major health‐care burden. Nat Rev Cardiol. 2024 Jan;2. doi:10.1038/s41569-023-00962-3
Sellner J, Taba P, Öztürk S, Helbok R. The need for neurologists in the care of COVID‐19 patients. Eur J Neurol. 2020;27(9):e31‐e32. doi:10.1111/ene.14257
Mitsikostas DD, Caronna E, De Tommaso M, et al. Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review. Eur J Neurol. 2024;e16251. doi:10.1111/ene.16251
Beghi E, Helbok R, Crean M, et al. The European Academy of Neurology COVID‐19 Registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID‐19. Eur J Neurol. 2021;28(10):3303‐3323. doi:10.1111/ene.14652
Bassetti CLA, Helbok R, Adorjan K, Falkai P. European Psychiatric Association – European Academy of Neurology statement on post‐COVID syndrome. Eur J Neurol. 2023;30(1):294‐295. doi:10.1111/ene.15572
Bassetti CLA, Helbok R, Adorjan K, Falkai P. European Psychiatric Association‐European Academy of Neurology statement on post‐COVID syndrome. Eur Psychiatry. 2022;65(1):e59. doi:10.1192/j.eurpsy.2022.2317
Moro E, Deuschl G, De Visser M, et al. A call from the European Academy of Neurology on COVID‐19. Lancet Neurol. 2020;19(6):482. doi:10.1016/S1474-4422(20)30151-4
Helbok R, Chou SHY, Beghi E, et al. NeuroCOVID: it's time to join forces globally. Lancet Neurol. 2020;19(10):805‐806. doi:10.1016/S1474-4422(20)30322-7
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683‐690. doi:10.1001/jamaneurol.2020.1127
Romoli M, Jelcic I, Bernard‐Valnet R, et al. A systematic review of neurological manifestations of SARS‐CoV‐2 infection: the devil is hidden in the details. Eur J Neurol. 2020;27(9):1712‐1726. doi:10.1111/ene.14382
Akhvlediani T, Jelcic I, Taba P, Pfausler B, Steiner I, Sellner J. What did we learn from the previous coronavirus epidemics and what can we do better: a neuroinfectiological point of view. Eur J Neurol. 2020;27(11):e69‐e72. doi:10.1111/ene.14395
Moro E, Priori A, Beghi E, et al. The International European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection. Eur J Neurol. 2020;27(9):1727‐1737. doi:10.1111/ene.14407
Román GC, Spencer PS, Reis J, et al. The neurology of COVID‐19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci. 2020;414:116884. doi:10.1016/j.jns.2020.116884
Beghi E, Moro E, Davidescu EI, et al. Comparative features and outcomes of major neurological complications of COVID ‐19. Eur J Neurol. 2023;30(2):413‐433. doi:10.1111/ene.15617
Beghi E, Helbok R, Ozturk S, et al. Short‐ and long‐term outcome and predictors in an international cohort of patients with neuro‐COVID‐19. Eur J Neurol. 2022;29(6):1663‐1684. doi:10.1111/ene.15293
Von Oertzen TJ, Macerollo A, Leone MA, et al. EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic. Eur J Neurol. 2021;28(1):7‐14. doi:10.1111/ene.14521
Bodini B, Moro E, Jaarsma J, et al. Lessons learned from people with neurological diseases at the time of COVID‐19: the EFNA‐EAN survey. Eur J Neurol. 2022;29(1):318‐323. doi:10.1111/ene.15087
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615. doi:10.1056/NEJMoa2034577
Sellner J, Jenkins TM, Von Oertzen TJ, et al. Primary prevention of COVID‐19: advocacy for vaccination from a neurological perspective. Eur J Neurol. 2021;28(10):3226‐3229. doi:10.1111/ene.14713
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384(5):403‐416. doi:10.1056/NEJMoa2035389
Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid‐19 vaccine. N Engl J Med. 2021;384(19):1824‐1835. doi:10.1056/NEJMoa2034201
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine (AZD1222) against SARS‐CoV‐2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99‐111. doi:10.1016/S0140-6736(20)32661-1
Knoll MD, Wonodi C. Oxford–AstraZeneca COVID‐19 vaccine efficacy. Lancet. 2021;397(10269):72‐74. doi:10.1016/S0140-6736(20)32623-4
Rakusa M, Öztürk S, Moro E, et al. COVID‐19 vaccination hesitancy among people with chronic neurological disorders: a position paper. Eur J Neurol. 2022;29(8):2163‐2172. doi:10.1111/ene.15368
Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid‐19 vaccine. N Engl J Med. 2022;386(20):1910‐1921. doi:10.1056/NEJMoa2200674
Troiano G, Nardi A. Vaccine hesitancy in the era of COVID‐19. Public Health. 2021;194:245‐251. doi:10.1016/j.puhe.2021.02.025
Fanciulli A, Skorić MK, Leys F, et al. EFAS/EAN survey on the influence of the COVID‐19 pandemic on European clinical autonomic education and research. Clin Auton Res. 2023;33(6):777‐790. doi:10.1007/s10286-023-00985-3
Habek M, Leys F, Krbot Skorić M, et al. Clinical autonomic nervous system laboratories in Europe: a joint survey of the European Academy of Neurology and the European Federation of Autonomic Societies. Eur J Neurol. 2022;29(12):3633‐3646. doi:10.1111/ene.15538
Sellner J, Jenkins TM, Von Oertzen TJ, et al. A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: the NeuroCOVID‐19 Task Force of the European Academy of Neurology. Eur J Neurol. 2021;28(11):3849‐3855. doi:10.1111/ene.14741
Rakusa M, Moro E, Akhvlediani T, et al. The COVID‐19 pandemic and neurology: a survey on previous and continued restrictions for clinical practice, curricular training, and health economics. Eur J Neurol. 2024;31(3):e16168. doi:10.1111/ene.16168
Wu Z, Zhang X, Huang Z, Ma K. SARS‐CoV‐2 proteins interact with alpha synuclein and induce Lewy body‐like pathology in vitro. Int J Mol Sci. 2022;23(6):3394. doi:10.3390/ijms23063394
Wang J, Dai L, Deng M, Xiao T, Zhang Z, Zhang Z. SARS‐CoV‐2 spike protein S1 domain accelerates α‐synuclein phosphorylation and aggregation in cellular models of synucleinopathy. Mol Neurobiol. 2023;28:2446‐2458. doi:10.1007/s12035-023-03726-9
Eberle RJ, Coronado MA, Gering I, et al. Tau protein aggregation associated with SARS‐CoV‐2 main protease. PLoS One. 2023;18(8):e0288138. doi:10.1371/journal.pone.0288138
Ramani A, Müller L, Ostermann PN, et al. SARS ‐CoV‐2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230. doi:10.15252/embj.2020106230
Chiricosta L, Gugliandolo A, Mazzon E. SARS‐CoV‐2 exacerbates beta‐amyloid neurotoxicity, inflammation and oxidative stress in Alzheimer's disease patients. Int J Mol Sci. 2021;22(24):13603. doi:10.3390/ijms222413603
Ma G, Zhang DF, Zou QC, et al. SARS‐CoV‐2 spike protein S2 subunit modulates γ‐secretase and enhances amyloid‐β production in COVID‐19 neuropathy. Cell Discov. 2022;8(1):99. doi:10.1038/s41421-022-00458-3
Stefanova N, Wenning GK. Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms. Nat Rev Neurosci. 2023;24(6):334‐346. doi:10.1038/s41583-023-00697-7
Cavallieri F, Fioravanti V, Bove F, et al. COVID‐19 and parkinsonism: a critical appraisal. Biomolecules. 2022;12(7):970. doi:10.3390/biom12070970